IP Library Granted Patent US 7,405,045
Granted Patent B2
US 7,405,045 · App. 11/492,392 · Granted Jul 29, 2008

Identification of viral agents in breast ducts and antiviral therapy therefore

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,405,045
App. No.
11/492,392
Granted
Jul 29, 2008
Kind
B2
Abstract

Methods and systems for identifying a virus in breast ducts are provided. In addition, antiviral therapy for treating a virally infected breast duct is also provided. Patients with a viral infection identified in the breast ducts may be at risk for developing breast precancer or cancer.

Claims (24)

1. A method for identifying a patient having an increased risk for developing breast precancer or breast cancer, said method comprising the following steps:

(a) introducing a ductal access tool into a plurality of breast ducts, said access tool comprising an elongated lumen;

(b) introducing a fluid into the breast ducts through said elongated lumen;

(c) retrieving ductal fluid samples from within the breast ducts through said lumen;

(d) combining said ductal fluid samples into a single fluid sample; and

(e) detecting a viral agent in the fluid sample.

2. A method as in claim 1 , wherein the viral agent is selected from the group consisting of a whole virus, a portion of a virus, a viral protein, a viral nucleic acid, and a viral marker, in the sample.

3. A method as in claim 1 , further comprising analyzing the ductal fluid for abnormal cytology.

4. A method as in claim 1 , wherein a viral agent is detected, and further comprising the steps of: periodically repeating steps (a)-(d); and monitoring a variable selected from the group consisting of a viral titer, concentration of a viral agent, and presence of a viral marker in the ductal fluid samples.

5. A method as in claim 4 , wherein the viral agent is monitored and the viral agent is selected from the group consisting of a whole virus, a portion of a virus, a viral protein, a viral nucleic acid, and a viral marker by taking repeated periodic ductal fluid samplings.

6. A method as in claim 4 , wherein the periodicity is selected from the group consisting of daily, weekly, biweekly, monthly, bimonthly, every six months, annually, and biannually.

7. A method as in claim 1 , wherein the viral agent is selected from the group consisting of papilloma virus, Epstein-barr virus, and herpes virus.

8. A method of treating a patient at risk for or having a breast precancer or breast cancer, said method comprising the following steps:

(a) introducing a ductal access tool into a plurality of breast ducts, said access tool comprising elongated lumen;

(b) introducing a fluid into the breast ducts through said elongated lumen;

(c) retrieving ductal fluid samples from within the breast ducts through said lumen;

(d) combining said ductal fluid samples into a single fluid sample; and

(e) detecting a viral agent in the retrieved fluid sample; and

(f) delivering to the patient a composition comprising an antiviral agent specific for the detected viral agent.

9. A method as in claim 8 , wherein the viral agent is selected from the group consisting of a whole virus, a portion of a virus, a viral protein, a viral nucleic acid, and a viral marker.

10. A method as in claim 8 , wherein the antiviral agent is delivered intraductally to the breast ducts in the breast in which the viral agent has been detected.

11. A method as in claim 8 , wherein the viral agent is selected from the group consisting of papilloma virus, Epstein-barr virus, and herpes virus.

12. A method as in claim 8 , wherein the antiviral agent is selected from the group consisting of an anti-HPV viral agent, and anti-EBV viral agent, and an anti-herpes viral agent.

13. A method as in claim 8 , wherein said delivering step includes delivering the composition comprising said antiviral agent systemically.

Assignments (7)
CORRECTIVE ASSIGNMENT TO CORRECT THE CHANGE OF NAME PREVIOUSLY RECORDED AT REEL: 051783 FRAME: 0477. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 10, 2020
From: ATOSSA GENETICS INC.
To: ATOSSA THERAPEUTICS, INC.
Reel/Frame 054372/0976 →
CHANGE OF NAME Recorded Feb 3, 2020
From: ATOSSA GENETICS INC.
To: ATOSSA THERAPEUTICS, INC.
Reel/Frame 051783/0477 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2012
From: HOLOGIC, INC.
To: ATOSSA GENETICS, INC.
Reel/Frame 027555/0377 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2012
From: CYTYC CORPORATION
To: HOLOGIC, INC.
Reel/Frame 027555/0260 →
TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Recorded Aug 26, 2010
From: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
To: HOLOGIC, INC.; R2 TECHNOLOGY, INC.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; DIRECT RADIOGRAPHY CORP.; CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS III, INC.; CYTYC PRENATAL PRODUCTS CORP.; THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 024892/0001 →
PATENT SECURITY AGREEMENT Recorded Jul 29, 2008
From: CYTYC CORPORATION
To: GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL AGENT
Reel/Frame 021301/0879 →
PATENT SECURITY AGREEMENT Recorded Oct 26, 2007
From: CYTYC CORPORATION
To: GOLDMAN SACHS CREDIT PARTNERS L.P.
Reel/Frame 020018/0529 →